its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration

Researchers running shorter cohorts at lower doses generally prefer the 20mg or 10mg formats
Nauck MA et al (2011): Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
The tirzepatide compound first came to market under the name Mounjaro, and it is a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 in one single molecule
it is only accessible through authorised clinical trials and is not available for routine prescribing
Sofwave Body is a non-invasive ultrasound treatment designed to lift and tighten skin by stimulating collagen production in targeted body areas like the upper arms, abdomen, buttocks, thighs, and knees